GlaxoSmithKline and Pfizer have agreed to pool their resources in HIV to create a new specialist company that will hold 19% of the market for HIV treatments. The two companies said that it will be more sustainable and broader in scope than either company's individually. GSK will have an 85% stake in the joint venture and Pfizer will have 15%.